The American Conference Institute's 19th annual Drug and Med Litigation Conference is the only event bringing together exceptional in-house presence on the faculty, the top defense firms representing biopharmaceutical and medical device companies, experienced jurists from around the country, the Food and Drug Administration and the Department of Justice.
Faegre Baker Daniels partners Bridget Ahmann and Andy Campbell will be speaking on two panels at the session entitled "A Practical Guide to Fighting the Continued Battle Over Preemption" on Wednesday, Dec. 10.
Ahmann will speak on the panel, "Defending Against Plaintiffs' Srongest Arguments Against Generic Preemption." Joining Erin Bosman and Glenn Kerner, Ahmann will discuss asserting a successful preemption defense and managing parallel claims in a post-Bartlett world. The panel will also dissect plaintiffs' best arguments for getting around preemption, provide updates on legislative and FDA developments regarding generic labeling, and demonstrate the use of an innovator liability theory in arguing for generic preemption.
Campbell and John Winter will present the portion of the discussion, "Strategies for Preserving the Medical Device Preemption Defense post-Stengel." They will explain the significance of the Supreme Court's denial of Cert in Stengel with respect to parallel state failure-to-warn claims, and implications cases like this have for drug and device litigation.